Scarinci Hollenbeck, LLC
The Firm
201-896-4100 info@sh-law.comFirm Insights
Author: Scarinci Hollenbeck, LLC
Date: August 20, 2014
The Firm
201-896-4100 info@sh-law.com
According to USA Today analysis of S&P Capital IQ data, however, there were at least 20 companies in the Standard & Poor’s 500 that reported paying an effective tax rate of 0 percent or lower for the second quarter of 2014. To be included in the analysis, the companies had to report positive earnings, including unusual items, before taxes.
One such company was drug-producing giant Merck, which had a negative effective tax rate of 7.5 percent for the second quarter, according to USA Today. In other words, taxpayers gave the company the equivalent of 7.5 percent of its quarterly profits in tax credits. Merck’s pre-tax income rose 52 percent during the quarter, coming to $1.9 billion.
This anomalous tax rate was attributed to the “beneficial impact of foreign earnings” in the company’s filing, but Merck also got a significant one-time tax benefit from an option exercise that involved AstraZeneca’s purchase of its interest in a partnership, the news source explained. AstraZeneca has also been under public scrutiny with regards to corporate tax practices.
President Barack Obama and other liberals have been making corporate taxation a major issue ahead of the 2014 midterm elections. Both sides of Congress agree that tax code reform is necessary, but many analysts agree that the political deadlock will prevent anything from happening before the elections determine the shape of the next two years.
As tax attorneys for Scarinci Hollenbeck, a regional business law firm with offices in New York, New Jersey, and Washington D.C., James F. McDonough and I are acclimated with corporate culture and the goings-on of corporations regarding income taxes. Check out some of latest post on this hot-button topic:
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.

On January 28, 2026, staff of the U.S. Securities and Exchange Commission’s Divisions of Corporation Finance, Investment Management, and Trading and Markets issued a joint statement clarifying how existing federal securities laws apply to tokenized securities. The SEC’s “Statement on Tokenized Securities” does not establish new law, but it does provide greater clarity on the […]
Author: Dan Brecher

Operating a business in the New Jersey and New York City metropolitan region offers incredible opportunities, but it also requires navigating a dense and highly regulated legal environment. From entity formation to regulatory compliance, seemingly minor legal oversights can expose business owners to significant risk. In our work with businesses throughout the region, our attorneys […]
Author: Dan Brecher

High-profile founder litigation is more than just a media spectacle. For startup founders, these cases underscore the legal and structural risks that can arise when rapid growth outpaces formal oversight. While launching a new company can be both an exciting and deeply rewarding endeavor, founders must be mindful that it also comes with significant risks. […]
Author: Dan Brecher

Every New Jersey company should periodically evaluate its governance framework. Strong corporate governance protects directors and officers, builds investor confidence, reduces litigation exposure, and positions a company for sustainable growth. The first quarter of the year is a great time to evaluate your corporate governance practices and perform any routine maintenance needed to keep that […]
Author: Ken Hollenbeck

Being served with a lawsuit is one of the most stressful legal events a business or individual can face. Whether the claim involves a contract dispute, an employment matter, an intellectual property issue, or another legal challenge, the actions you take in the first few days can significantly shape the outcome of your case. Acting […]
Author: Robert E. Levy

Special Purpose Acquisition Companies (SPACs) continue to gain momentum as we move through 2026. After enduring a significant contraction following the 2021 boom and the regulatory scrutiny that followed, SPAC activity rebounded sharply in 2025 and now carries forward into 2026 with real momentum. The SPAC resurgence reflects broader improvements in both market conditions and the […]
Author: Dan Brecher
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.
Consider subscribing to our Firm Insights mailing list by clicking the button below so you can keep up to date with the firm`s latest articles covering various legal topics.
Stay informed and inspired with the latest updates, insights, and events from Scarinci Hollenbeck. Our resource library provides valuable content across a range of categories to keep you connected and ahead of the curve.
Let`s get in touch!
Sign up to get the latest from the Scarinci Hollenbeck, LLC attorneys!